Gout: diagnosis and management
In development [GID-NG10151] Expected publication date: 13 June 2022
Search results
561 results
-
-
Depression in adults: treatment and management (update)
In development [GID-CGWAVE0725] Expected publication date: 12 May 2022
-
Otitis media with effusion in under 12s: surgery
In development [GID-NG10193] Expected publication date: TBC
-
Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 06 July 2022
-
Stroke rehabilitation in adults
In development [GID-NG10175] Expected publication date: 14 December 2022
-
Adults with complex needs: social work interventions including assessment, care management and support
In development [GID-NG10145] Expected publication date: 27 April 2022
-
Integrated health and social care for people experiencing homelessness
In development [GID-NG10170] Expected publication date: 16 March 2022
-
Self harm: assessment, management and preventing recurrence
In development [GID-NG10148] Expected publication date: 18 May 2022
-
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
In development [GID-NG10141] Expected publication date: 17 November 2021
-
Neonatal infection: antibiotics for prevention and treatment
In development [GID-NG10111] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)
In development [GID-TA10366] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
In development [GID-TA10208] Expected publication date: TBC
-
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development [GID-TA10250] Expected publication date: TBC
-
Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605
In development [GID-TA10488] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
In development [GID-TA10607] Expected publication date: TBC
-
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]
In development [GID-TA10589] Expected publication date: TBC
-
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]
In development [GID-TA10573] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]
In development [GID-TA10583] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]
In development [GID-TA10571] Expected publication date: 25 August 2021
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]
In development [GID-TA10568] Expected publication date: TBC
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
In development [GID-TA10617] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
In development [GID-TA10429] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260
In development [GID-TA10309] Expected publication date: TBC
-
Ibrutinib for untreated mantle cell lymphoma (ID1221)
In development [GID-TA10185] Expected publication date: TBC
-
Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]
In development [GID-TA10352] Expected publication date: 13 October 2021
-
Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]
In development [GID-TA10656] Expected publication date: 02 March 2022
-
Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]
In development [GID-TA10633] Expected publication date: TBC
-
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683
In development [GID-TA10537] Expected publication date: TBC
-
Carotuximab with pazopanib for treating advanced angiosarcoma ID1503
In development [GID-TA10401] Expected publication date: TBC
-
Asunercept for treating glioblastoma [1301]
In development [GID-TA10227] Expected publication date: TBC
-
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
In development [GID-TA10225] Expected publication date: TBC
-
Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538
In development [GID-TA10422] Expected publication date: TBC
-
Furosemide micro-pump for treating oedema associated with heart failure (ID1061)
In development [GID-TA10179] Expected publication date: TBC
-
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492
In development [GID-TA10441] Expected publication date: TBC
-
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
In development [GID-TA10446] Expected publication date: TBC